Compare NUVB & NAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NUVB | NAD |
|---|---|---|
| Founded | 2018 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | N/A | N/A |
| Metric | NUVB | NAD |
|---|---|---|
| Price | $6.01 | $12.05 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $10.44 | N/A |
| AVG Volume (30 Days) | ★ 6.3M | 595.7K |
| Earning Date | 03-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.35% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $26,748,000.00 | N/A |
| Revenue This Year | $616.63 | N/A |
| Revenue Next Year | $202.59 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1137.19 | N/A |
| 52 Week Low | $1.54 | $9.56 |
| 52 Week High | $9.75 | $11.64 |
| Indicator | NUVB | NAD |
|---|---|---|
| Relative Strength Index (RSI) | 29.46 | 47.86 |
| Support Level | $6.07 | $12.06 |
| Resistance Level | $6.63 | $12.12 |
| Average True Range (ATR) | 0.53 | 0.07 |
| MACD | -0.39 | -0.00 |
| Stochastic Oscillator | 11.03 | 36.67 |
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Nuveen Quality Municipal Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempted from regular federal income tax by investing in tax-exempt municipal securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.